Gestala – Weekly Recap

Gestala continued to strengthen its position in the emerging ultrasound-based brain-computer interface market this week, with developments spanning funding, scientific governance, and NeuroAI capabilities. The company, which focuses on non-invasive, whole-brain read-write technology, highlighted new advisory appointments and capital deployment plans in recent communications.

Gestala recently closed an angel funding round of RMB 150 million, or about $21 million, to support its ultrasound-driven neuromodulation and BCI platform. Management indicated that the capital will be directed toward clinical research, regulatory engagement, and prototype development, reflecting a research-intensive strategy in a highly regulated medtech domain.

Founder and CEO Phoenix Peng outlined the company’s roadmap at Bank of America’s Breakthrough Technology Dialogue APAC in Singapore and in an interview on Bloomberg TV’s The China Show. Peng positioned Gestala within a small global cohort of ultrasound-focused neurotechnology firms and noted that peers such as Merge Labs may be viewed as both competitors and potential partners.

On the scientific front, Gestala expanded its Scientific Advisory Board with leading academic figures in neuroscience and NeuroAI. Earlier, the company added Professor Trevor Robbins, a Cambridge-based expert in cognitive and behavioral neuroscience, to help guide focused ultrasound neuromodulation studies targeting psychiatric and neurological disorders.

This week, Gestala further reinforced its advisory bench by appointing Professor Jianfeng Feng as the second distinguished member of its Scientific Advisory Board. Feng holds senior roles at Fudan University and the University of Warwick and is recognized for his work in computational neuroscience, machine learning, and biomedical big data, including development of a large-scale Digital Twin Brain platform.

Gestala plans to integrate its whole-brain ultrasound read-write capabilities with Feng’s multimodal data expertise in NeuroAI and mathematical modeling. This combination is expected to support development of advanced digital brain twins and diagnostic tools for brain disorders, potentially enhancing the company’s differentiated intellectual property and data-driven neurotechnology pipeline.

The bolstered advisory team is also intended to improve study design, translational research quality, and clinical collaboration prospects. These enhancements may strengthen Gestala’s credibility with partners, regulators, and investors, while supporting long-term commercialization opportunities in NeuroAI and brain health applications.

Overall, the week underscored Gestala’s dual focus on capital strength and scientific depth as it advances its non-invasive ultrasound BCI platform. By pairing fresh funding with high-profile advisory appointments, the company signaled a deliberate strategy to build both technological and evidence-based advantages in a competitive neurotechnology landscape.